← Back to patent-cliff list
CAS 2131743-82-1
2-[(7-Azaindole-5-yl)oxy]-4-bromobenzoic acid
Codes: (XXXIX)992511-1-f
Application context (from source-drug indications)
Chronic lymphocytic leukaemiaLisaftoclaxAcute promyelocytic leukaemiaLisaftoclaxMyelodysplastic syndromeLisaftoclaxAcute myeloid leukaemiaLisaftoclaxDiffuse large B-cell lymphomaLisaftoclaxSystemic lupus erythematosusLisaftoclax
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Lisaftoclax | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
4-(4-[[6-(4-Chlorophenyl)spiro[3.5]non-6-en-7-yl]methyl]piperazin-1-yl)-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzoic acid→1-[[6-(4-Chlorophenyl)spiro[3.5]non-6-en-7-yl]methyl]piperazine→2-[(7-Azaindole-5-yl)oxy]-4-bromobenzoic acid
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.